These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

935 related items for PubMed ID: 18710798

  • 21. 5-HT6 receptor antagonist SB-399885 potentiates haloperidol and risperidone-induced dopamine efflux in the medial prefrontal cortex or hippocampus.
    Li Z, Huang M, Prus AJ, Dai J, Meltzer HY.
    Brain Res; 2007 Feb 23; 1134(1):70-8. PubMed ID: 17207474
    [Abstract] [Full Text] [Related]

  • 22. F15063, a potential antipsychotic with dopamine D(2)/D(3) receptor antagonist and 5-HT(1A) receptor agonist properties: influence on immediate-early gene expression in rat prefrontal cortex and striatum.
    Bruins Slot LA, Lestienne F, Grevoz-Barret C, Newman-Tancredi A, Cussac D.
    Eur J Pharmacol; 2009 Oct 12; 620(1-3):27-35. PubMed ID: 19695244
    [Abstract] [Full Text] [Related]

  • 23. Blockade of phencyclidine-induced hyperlocomotion by clozapine and MDL 100,907 in rats reflects antagonism of 5-HT2A receptors.
    Maurel-Remy S, Bervoets K, Millan MJ.
    Eur J Pharmacol; 1995 Jul 04; 280(2):R9-11. PubMed ID: 7589172
    [Abstract] [Full Text] [Related]

  • 24. Time course of dopamine-D2 and serotonin-5-HT2 receptor occupancy rates by haloperidol and clozapine in vivo.
    Sumiyoshi T, Kido H, Sakamoto H, Urasaki K, Suzuki K, Yamaguchi N, Mori H, Shiba K, Yokogawa K, Ichimura F.
    Jpn J Psychiatry Neurol; 1993 Mar 04; 47(1):131-7. PubMed ID: 8411785
    [Abstract] [Full Text] [Related]

  • 25. Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients.
    Bressan RA, Erlandsson K, Jones HM, Mulligan R, Flanagan RJ, Ell PJ, Pilowsky LS.
    Am J Psychiatry; 2003 Aug 04; 160(8):1413-20. PubMed ID: 12900302
    [Abstract] [Full Text] [Related]

  • 26. In vivo dopamine-D2 and serotonin-5-HT2 receptor binding study of risperidone and haloperidol.
    Sumiyoshi T, Kido H, Sakamoto H, Urasaki K, Suzuki K, Yamaguchi N, Mori H, Shiba K, Yokogawa K.
    Pharmacol Biochem Behav; 1994 Mar 04; 47(3):553-7. PubMed ID: 7516078
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Dose-related effects of clozapine and risperidone on the pattern of brain regional serotonin and dopamine metabolism and on tests related to extrapyramidal functions in rats.
    Batool F, Hasnat A, Haleem MA, Haleem DJ.
    Acta Pharm; 2010 Jun 04; 60(2):129-40. PubMed ID: 21134850
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats.
    Kapur S, Langlois X, Vinken P, Megens AA, De Coster R, Andrews JS.
    J Pharmacol Exp Ther; 2002 Sep 04; 302(3):1129-34. PubMed ID: 12183672
    [Abstract] [Full Text] [Related]

  • 32. Discriminative stimulus properties of the atypical antipsychotic amisulpride: comparison to its isomers and to other benzamide derivatives, antipsychotic, antidepressant, and antianxiety drugs in C57BL/6 mice.
    Donahue TJ, Hillhouse TM, Webster KA, Young R, De Oliveira EO, Porter JH.
    Psychopharmacology (Berl); 2017 Dec 04; 234(23-24):3507-3520. PubMed ID: 28921163
    [Abstract] [Full Text] [Related]

  • 33. Increasing D2 affinity results in the loss of clozapine's atypical antipsychotic action.
    Kapur S, McClelland RA, VanderSpek SC, Wadenberg ML, Baker G, Nobrega J, Zipursky RB, Seeman P.
    Neuroreport; 2002 May 07; 13(6):831-5. PubMed ID: 11997696
    [Abstract] [Full Text] [Related]

  • 34. The antipsychotic potential of l-stepholidine--a naturally occurring dopamine receptor D1 agonist and D2 antagonist.
    Natesan S, Reckless GE, Barlow KB, Odontiadis J, Nobrega JN, Baker GB, George SR, Mamo D, Kapur S.
    Psychopharmacology (Berl); 2008 Aug 07; 199(2):275-89. PubMed ID: 18521575
    [Abstract] [Full Text] [Related]

  • 35. S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: II. Functional profile and a multiparametric comparison with haloperidol, clozapine, and 11 other antipsychotic agents.
    Millan MJ, Brocco M, Rivet JM, Audinot V, Newman-Tancredi A, Maiofiss L, Queriaux S, Despaux N, Peglion JL, Dekeyne A.
    J Pharmacol Exp Ther; 2000 Jan 07; 292(1):54-66. PubMed ID: 10604931
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. PET analysis indicates atypical central dopamine receptor occupancy in clozapine-treated patients.
    Farde L, Nordström AL.
    Br J Psychiatry Suppl; 1992 May 07; (17):30-3. PubMed ID: 1358126
    [Abstract] [Full Text] [Related]

  • 39. The antipsychotics olanzapine, risperidone, clozapine, and haloperidol are D2-selective ex vivo but not in vitro.
    McCormick PN, Kapur S, Graff-Guerrero A, Raymond R, Nobrega JN, Wilson AA.
    Neuropsychopharmacology; 2010 Jul 07; 35(8):1826-35. PubMed ID: 20410873
    [Abstract] [Full Text] [Related]

  • 40. Prolactinemia is uncoupled from central D2/D3 dopamine receptor occupancy in amisulpride treated patients.
    Bressan RA, Erlandsson K, Spencer EP, Ell PJ, Pilowsky LS.
    Psychopharmacology (Berl); 2004 Sep 07; 175(3):367-73. PubMed ID: 14997280
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 47.